Data supported selection of EP262 as a potent, highly selective development candidate
Clinical development of EP262 recently initiated as a novel treatment for a broad range of mast cell mediated diseases including chronic spontaneous…
– Results show the impact of attacks on mental health, daily activities, and quality of life in people living with HAE -
– Real-world data demonstrate treatment burden associated with on-demand parenteral HAE therapies -
CAMBRIDGE,…